<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75541">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01891344</url>
  </required_header>
  <id_info>
    <org_study_id>CO-338-017</org_study_id>
    <nct_id>NCT01891344</nct_id>
  </id_info>
  <brief_title>A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)</brief_title>
  <acronym>ARIEL2</acronym>
  <official_title>A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clovis Oncology, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>United Kingdom: National Health Service</authority>
    <authority>France: Ministry of Health</authority>
    <authority>Spain: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which patients with ovarian, fallopian tube, and
      primary peritoneal cancer will best respond to treatment with rucaparib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rucaparib is an orally available, small molecule inhibitor of poly-adenosine diphosphate
      [ADP] ribose polymerase (PARP) being developed for treatment of ovarian cancer associated
      with homologous recombination (HR) DNA repair deficiency (HRD).  The safety and efficacy of
      rucaparib has been evaluated in several Phase 1 and Phase 2 studies.  An oral formulation is
      the focus of current development efforts.  Rucaparib is currently being investigated as
      monotherapy in patients with cancer associated with breast cancer susceptibility gene 1
      (BRCA1) or BRCA2 mutations.

      Clinical data with PARP inhibitors indicate there is an ovarian cancer patient population
      beyond just those with germline BRCA (gBRCA) mutations that may benefit from treatment with
      a PARP inhibitor.  This study will define a molecular signature of HRD in ovarian cancer
      that correlates with response to rucaparib and enables selection of appropriate ovarian
      cancer patients for treatment with rucaparib.  The HRD signature will be based on an
      association between the extent of genomic scarring (a downstream consequence of HRD) in a
      patient's tumor and observed clinical benefit from rucaparib treatment.  Genomic scarring
      can be assessed by quantifying the extent of loss of heterozygosity across the tumor genome
      (tumor genomic LOH).  One of the main advantages of detecting tumor genomic LOH is that it
      can identify HRD tumors regardless of the underlying mechanisms, which include both known
      (i.e., BRCA mutations) and unknown genetic and other mechanisms.

      Once determined, this signature will be prospectively applied in the final analysis of the
      planned Phase 3 pivotal study (ARIEL3). This Phase 2 study (ARIEL2) will also compare
      archival versus recently collected tumor tissue in order to validate the use of archival
      tumor tissue for assessment of HRD status in ARIEL3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival per RECIST version 1.1</measure>
    <time_frame>Screening; at the end of every 8 weeks (±4 days) of treatment; at disease progression; study data collection expected to last for ~2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate achieved (from baseline to disease progression) per RECIST version 1.1 and GCIG CA-125 response criteria.</measure>
    <time_frame>Screening; at the end of every 8 weeks (±4 days) of treatment; at disease progression; study data collection expected to last for ~2 years (RECIST v1.1).</time_frame>
    <safety_issue>No</safety_issue>
    <description>Screening, Day 1 of every cycle, at the end of every 8 weeks (±4 days) of treatment, as clinically indicated, and at disease progression (GCIG CA-125 response criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response per RECIST version 1.1</measure>
    <time_frame>Screening; at the end of every 8 weeks (±4 days) of treatment; at disease progression; study data collection expected to last for ~2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, clinical laboratory abnormalities, and dose modifications</measure>
    <time_frame>Every day starting with signing of consent until 28 days after discontinuation of treatment; study data collection expected to last for ~2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough (Cmin) level of rucaparib concentrations</measure>
    <time_frame>2 weeks, 1 month, 2 months and 3 months after 1st dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients with platinum-sensitive, relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer will take oral rucaparib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral rucaparib</intervention_name>
    <description>All patients will ingest rucaparib twice a day continuously until disease progression.  Patients may take rucaparib on an empty stomach or with food. Each dose should be taken with at least 8 oz (240 mL) of room temperature water.  Tablets should be swallowed whole.  Each patient will take the Recommended Phase 2 Dose established in the CO-338-010 study.</description>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <other_name>CO-338</other_name>
    <other_name>PF 01367338</other_name>
    <other_name>AG 14699</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of high-grade epithelial ovarian (serous or endometrioid
             histology), fallopian tube, or primary peritoneal cancer

          -  Relapsed/progressive disease as confirmed by CT scan

          -  Received ≥1 prior platinum-based treatment regimen

          -  Received platinum-based regimen as last treatment; continuous or switch maintenance
             treatment as part of this regimen is permitted

          -  Sensitive to last platinum regimen (disease progression &gt;6 months after the last dose
             of platinum)

          -  If &lt;55 years of age at diagnosis, prior history of breast cancer, or close relative
             (first or second degree) with ovarian cancer or early onset (&lt;age 50) breast cancer,
             must have been previously tested for gBRCA mutation; after 15 patients harboring the
             gBRCA mutation are enrolled, no additional patients with a known gBRCA mutation will
             be allowed to enroll.

          -  Have biopsiable and measurable disease

        Exclusion Criteria:

          -  History of prior cancers except for those that have been curatively treated, with no
             evidence of cancer currently (provided all chemotherapy was completed &gt;6 months prior
             and/or bone marrow transplant &gt;2 years prior to first dose of rucaparib).

          -  Prior treatment with any PARP inhibitor

          -  Symptomatic and/or untreated central nervous system metastases

          -  Pre-existing duodenal stent and/or any other gastrointestinal disorder or defect that
             would, in the opinion of the Investigator, interfere with absorption of rucaparib
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clovis Oncology Clinical Trial Information</last_name>
    <email>clinicaltrialinfo@clovisoncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Center</last_name>
      <email>kcenter@uacc.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Jude Heritage Medical Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayle Madden-Mathes</last_name>
      <email>gayle.madden-mathes@stjoe.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Branch</last_name>
      <email>sbranch@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara Pennacchio</last_name>
      <email>cara.pennacchio@cc.ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Integrative Cancer Care</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Free</last_name>
      <email>jfree@ohmacc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Coast Medical Oncology</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Meija</last_name>
      <email>mariameija@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Powell</last_name>
      <email>ashleypowell@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbie Donnachaidh</last_name>
      <email>bobbie.donnachaidh@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Horizon BioAdvance</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Long</last_name>
      <email>along@horizonbioadvance.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Wolfson</last_name>
      <email>dwolfso3@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Llazar Cuko</last_name>
      <email>lcuko@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberley MacNeill</last_name>
      <email>kimberley_macneill@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynne Lippmann</last_name>
      <email>lippmannl@wudosis.wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Katz</last_name>
      <email>donnakatz@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy McGuinn</last_name>
      <email>bell-mck@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hope - A Woman's Cancer Institute</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisha Meade</last_name>
      <email>ameade@hopewcc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kori Fenner</last_name>
      <email>kori.fenner@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carie Snowbarger</last_name>
      <email>carie-snowbarger@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Intake Number</last_name>
      <phone>888-309-2427</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taren Johnston</last_name>
      <email>tjohnston@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington - Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Dherin</last_name>
      <email>mdherin@fhcrc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christie Norris</last_name>
      <email>christie.norris@sesiahs.health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Campbell</last_name>
      <email>jenny_campbell@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Flinders Cancer Clinic - Flinders Medical Centre (FMC)</name>
      <address>
        <city>Bedfork Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Richards</last_name>
      <email>alison.richards@health.sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marian Lieschke</last_name>
      <email>marian.lieschke@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Crown Princess Mary Cancer Centre</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serene Leow</last_name>
      <email>serene.leow@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vancouver Cancer Centre, British Columbia Cancer Agency (BCCA)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kikine Capier</last_name>
      <email>kcapier@bccancer.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Bailey</last_name>
      <email>laurad.bailey@lhsc.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doreen Whelan</last_name>
      <email>dwhelan@toh.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes Walters</last_name>
      <email>agnes.walters@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedicte Benetreau</last_name>
      <email>b.benetreau@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <state>Basse-Normandie</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Hotel-Dieu</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Ile-de-France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Vallee</last_name>
      <email>melissa.vallee@gustaveroussy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrenees</state>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <state>Pays de la Loire</state>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <state>Rhone-Alpes</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Benite</city>
        <state>Rhone-Alpes</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Padros</last_name>
      <email>opadros@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Valencia de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Calabuig</last_name>
      <email>coordinacion@fincivo.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Blasco</last_name>
      <email>iblasco@incliva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G120YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St James University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS97TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB20QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>W1T4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust - Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W120HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M204BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE77DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jared Thornton</last_name>
      <email>jared.thornton@ncl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://arielstudy.com/</url>
    <description>ARIEL trials website</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>June 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cancer</keyword>
  <keyword>peritoneal cancer</keyword>
  <keyword>platinum sensitive</keyword>
  <keyword>relapsed disease</keyword>
  <keyword>PARP Inhibitor</keyword>
  <keyword>rucaparib</keyword>
  <keyword>homologous recombination</keyword>
  <keyword>homologous recombination deficiency</keyword>
  <keyword>genomic scarring</keyword>
  <keyword>loss of heterozygosity</keyword>
  <keyword>CO-338</keyword>
  <keyword>PF 01367338</keyword>
  <keyword>AG 14699</keyword>
  <keyword>platinum sensitive ovarian cancer</keyword>
  <keyword>platinum sensitive fallopian tube cancer</keyword>
  <keyword>platinum sensitive primary peritoneal cancer</keyword>
  <keyword>platinum sensitive peritoneal cancer</keyword>
  <keyword>gynecological cancer</keyword>
  <keyword>Clovis</keyword>
  <keyword>Clovis Oncology</keyword>
  <keyword>ARIEL2</keyword>
  <keyword>ARIEL 2</keyword>
  <keyword>ARIEL3</keyword>
  <keyword>ARIEL 3</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
